Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE) announced that PROFILE 1014, a phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. Pfizer Inc. (NYSE:PFE) stock performance was 1.13% in last session and finished the day at $32.18. Traded volume was 31.58million shares in the last session and the average volume of the stock remained 26.31million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

US drug makers Merck and Co. Inc. and Bristol-Myers Squibb Co. (NYSE:BMY) who had exited India earlier re-entered the market in 2005 with fresh investments. They have also made joint ventures and forged strategic alliances with local firms. Bristol-Myers Squibb Co (NYSE:BMY) rose 3.17 percent to $52.66 Wednesday on volume of 16.14million shares. The intra-day range of the stock was $51.24 to $52.93. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $87.26billion.

Gilead Sciences Inc. (NASDAQ:GILD) tumbled last week, supposedly on news of patent infringement lawsuits in Europe. The stock actually peaked in February and broke down below its June 2013 trendline a week before the news came out. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on Mar 26, 2014 reported a decrease of -0.34% to the closing price of $72.78. Its fifty two weeks range is $45.11 -$84.88. The total market capitalization recorded $111.92billion. The overall volume in the last trading session was 15.72million shares. In its share capital, GILD has 1.53billion outstanding shares.

Shares of MannKind Corporation (NASDAQ:MNKD) were the recipient of some unusual options trading activity on Monday. Traders purchased 21,101 call options on the company, AnalystRatings.NET reports. A number of analysts have recently weighed in on MNKD shares. Analysts at Zacks reiterated a “neutral” rating on shares of MannKind Corporation (NASDAQ:MNKD) in a research note on Thursday, February 20th. They now have a $6.25 price target on the stock. Separately, analysts at MLV & Co. reiterated a “buy” rating on shares of MannKind Corporation (NASDAQ:MNKD) in a research note on Thursday, February 20th. On Wednesday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -7.24% to close the day at $5.38. Company monthly performance is recorded as -17.74%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 4.67%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone